The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.
 
Jason W.D. Hearn
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Sanofi (Inst); Sotio (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Nima Almassi
No Relationships to Disclose
 
Chad A. Reichard
No Relationships to Disclose
 
Chandana A. Reddy
Other Relationship - International Journal of Radiation Oncology Biology Physics
 
Brian Hobbs
Consulting or Advisory Role - Simulstat
 
David Frazier Jarrard
No Relationships to Disclose
 
Yu-Hui Chen
Employment - Constellation Pharmaceuticals (I); Flagship VL59 (I)
Stock and Other Ownership Interests - Constellation Pharmaceuticals (I)
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai; Eisai; EMD Serono; Genentech/Roche; Incyte; Pfizer
Research Funding - BioClin Therapeutics (Inst); Genentech (Inst); Janssen Oncology (Inst); Merck (Inst); Seagen (Inst)
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Genentech/Roche; Medivation/Astellas; Merck; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Pfizer; Sanofi
 
Michael Anthony Carducci
Consulting or Advisory Role - Abbvie; Astellas Pharma; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); pfizer (Inst)
 
Robert S. DiPaola
No Relationships to Disclose
 
Nima Sharifi
Consulting or Advisory Role - Asana Biosciences; Pfizer; Tolmar
Research Funding - Druggablity Technologies; Janssen Oncology
Patents, Royalties, Other Intellectual Property - A patent application has been filed by Cleveland Clinic for a method of steroid-dependent disease treatment based on HSD3B1. Nima Sharifi is a co-inventor on this patent application